ENTITY

Sichuan Kelun-Biotech Biopharm (6990 HK)

31
Analysis
Health CareChina
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates biotechnology businesses. The Company develops and provides biological drugs, chemical raw materials, antibody conjugating drugs, innovative drugs, and other products. Kelun Biotech also operates import and export businesses.
more
29 May 2024 09:47

Sichuan Kelun-Biotech Biopharm (6990.HK) - Current High Valuation Is Not Secure

The market has high hopes for SKB264's clinical data on NSCLC/TNBC, which will impact Akeso's future expectations. Be cautious of share price...

Logo
303 Views
Share
21 Aug 2024 18:32Broker

Kelun-Biotech (6990 HK) - Innovative Bispecific ADC Product Licensed to MSD

Kelun-Biotech recorded RMB1.38bn (+32% YoY) revenue in 1H24, including a total of US$90mn (or RMB641mn) milestone payments from MSD regarding...

Logo
157 Views
Share
07 Jun 2024 07:53Broker

Kelun-Biotech (6990 HK) - Data Release at ASCO Further Confirmed SKB264’s Potential

With Trodelvy and Dato-DXd missing the OS endpoints in Ph3 trials for 2/3L NSCLC, we think SKB264 will enjoy a better positioning in the global...

Logo
290 Views
Share
08 May 2024 10:09

Sichuan Kelun-Biotech Biopharm (6990.HK) - Once the Products Hit the Market, Good Story May Stop

Kelun Bio seeks to raise HKD540.5M in net proceeds from Share Placement. The Placing Price is HKD150/share (6.8% discount to Last Traded Price of...

Logo
836 Views
Share
27 Mar 2024 18:46Broker

Kelun-Biotech (6990 HK) - Intense Data Release to Further Validate the Global Potential of SKB264

In Mar 2023, SKB received around RMB1.21bn upfront payment from MSD for out-licensing certain pre-clinical ADC assets, a portion of which was...

Logo
246 Views
Share
x